# Parabilis Medicines, Inc.: overview PBLS · Nasdaq · CIK 1657677 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pbls.md) · [Financials](/companies/pbls/financials.md) · [Filings](/companies/pbls/filings.md) · [Insiders](/companies/pbls/insiders.md) Latest reported revenue: [$148.0k](/filings/0001193125-26-349168.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-349168). ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | [0.0](/filings/0001193125-26-349168.md) | not reported | [148](/filings/0001193125-26-349168.md) | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(34382.4%)](/filings/0001193125-26-349168.md) | | Net margin | % | not reported | not reported | not reported | [(35448.0%)](/filings/0001193125-26-349168.md) | | Diluted EPS | $ per share | not reported | [(22.28)](/filings/0001193125-26-349168.md) | not reported | [(2.32)](/filings/0001193125-26-349168.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL not reported. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pbls/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $791.9m | 28,933,371 | | New +28,933,371 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $281.7m | 10,292,735 | | New +10,292,735 | | [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $175.5m | 6,412,780 | | New +6,412,780 | | [venBio Partners LLC](/funds/1776382.md) | 2026-06-30 | $144.1m | 5,266,697 | | New +5,266,697 | | [Alphabet Inc.](/funds/1652044.md) | 2026-06-30 | $134.6m | 4,919,498 | | New +4,919,498 | | [Nextech Invest Ltd.](/funds/1595430.md) | 2026-06-30 | $127.6m | 4,663,176 | | New +4,663,176 | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $126.3m | 4,615,612 | | New +4,615,612 | | [REGENERON PHARMACEUTICALS, INC.](/funds/872589.md) | 2026-06-30 | $114.0m | 4,166,666 | | New +4,166,666 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $81.9m | 2,992,259 | | New +2,992,259 | | [FARALLON CAPITAL MANAGEMENT, L.L.C.](/funds/909661.md) | 2026-06-30 | $64.8m | 2,368,200 | | New +2,368,200 | ## Recent filings [All 62 filings](/companies/pbls/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-15 | 16:15 ET | [8-K](/filings/0001193125-26-391952.md) | 7.01 Regulation FD disclosure | 0001193125-26-391952 | | 2026-09-02 | 16:05 ET | [8-K](/filings/0001193125-26-380171.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-380171 | | 2026-08-25 | 16:10 ET | [8-K](/filings/0001193125-26-365132.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-365132 | | 2026-08-13 | 16:08 ET | [10-Q](/filings/0001193125-26-349168.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349168 | | 2026-08-13 | 07:19 ET | [8-K](/filings/0001193125-26-347869.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-347869 | | 2026-06-18 | 16:09 ET | [SCHEDULE 13D](/filings/0001346824-26-000178.md) | Ownership report, active investor | 0001346824-26-000178 | | 2026-06-11 | 16:12 ET | [8-K](/filings/0001193125-26-267550.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-267550 | | 2026-06-09 | 06:09 ET | [S-1/A](/filings/0001193125-26-262880.md) | Registration statement, amended | 0001193125-26-262880 | | 2026-06-04 | 06:16 ET | [S-1/A](/filings/0001193125-26-256398.md) | Registration statement, amended | 0001193125-26-256398 | | 2026-05-27 | 16:55 ET | [S-1/A](/filings/0001193125-26-242067.md) | Registration statement, amended | 0001193125-26-242067 | ## Latest annual report No annual report is in coverage. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b5586e8b-bff7-405a-b0a4-3983cdbbe6a3) ## About the filer - CIK: 1657677 - Tickers: PBLS - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.